Revium Recovery Inc. (RVRC)

Overview

Revium Rx, initially known as Revium Recovery Inc., is a pre-clinical stage biopharmaceutical company that has been at the forefront of developing cutting-edge pharmaceutical candidates since its inception in 1997. Based in Herzliya, Israel, the company has carved a niche in the industry through its innovative approach to drug development. Specializing in nano-liposomal particles (NLP)-based technologies, Revium Rx has dedicated itself to creating advanced formulations for several critical healthcare areas, including antibiotic therapies, cancer treatments, and immunizations. The transition from Revium Recovery Inc. to Revium Rx in December 2024 marked a significant milestone in the company’s evolution, reflecting its refined focus and commitment to revolutionizing patient care through scientific innovation.

Products and Services

Revium Rx's product development strategy centers around leveraging nano-liposomal particles (NLP) technology to enhance the efficacy and delivery of pharmaceutical compounds. The company's portfolio includes:

• Nanoparticles-based formulation of a potent antibiotic: This innovative approach aims to overcome the challenges associated with traditional antibiotic delivery methods. By encapsulating antibiotics in nanoparticles, Revium Rx seeks to enhance drug solubility, stabilize the therapeutic agents, and deliver the medication directly to the infection site, potentially reducing side effects and improving patient outcomes.
• Novel adjuvant for cancer therapies: Recognizing the complexity of cancer and the necessity for more effective treatments, Revium Rx is developing a novel adjuvant designed to boost the efficacy of existing cancer therapies. This adjuvant, based on liposomal technology, is intended to enhance the immune system's response to cancer cells, making other treatments more effective at targeting and eradicating tumors.
• Novel immunization based on liposomal protein-loaded technology: As part of its commitment to advancing public health, Revium Rx is also working on a new class of vaccines. Using liposomal protein-loaded technology, these vaccines aim to provide more robust and durable immune responses against various pathogens, potentially transforming the landscape of preventive medicine. This technology seeks to improve vaccine stability, delivery, and efficacy, thereby offering better protection with fewer doses.